Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report

Annals of Hematology 2026 Open access

Read full text
Authors: Klaus Geissler, Gerlinde Mitterbauer‐Hohendanner, Roland Jäger
DOI: 10.1007/s00277-026-06850-3
Cited by: 0
References: 11

Abstract

Oral decitabine/cedazuridine has been studied in chronic myelomonocytic leukemia (CMML) recently but the molecular changes during this treatment have not been reported so far. We report a CMML patient who was treated with oral decitabine/cedazuridine and showed a stepwise loss of KRAS mutation and trisomy 8 while the TET2 mutated clone gradually increased eventually resulting in clonal hematopoiesis. This case report highlights the disease modifying potential of this treatment in single CMML patients.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Annals of Hematology
Volume
105
Issue
3
Pages
78–78
Publication date
4 February 2026
Language
EN